Simple Summary Bladder cancer is the 10th most common cancer in the world, and its
incidence is gradually rising worldwide. Currently, radical cystectomy with pelvic …

Organ-sparing combined-modality treatment for muscle-invasive bladder cancer remains
underutilized despite high-quality evidence regarding its efficacy, safety, and preservation of …

There is a well-documented problem of inferior outcome of muscle-invasive bladder cancer
(MIBC) after radical cystectomy (RC) in women. However, previous studies were conducted …

Simple Summary Understanding how effective a treatment is before a major bladder surgery
can help doctors to plan better patient care. Our research investigated the survival rates of …

Background: Neutrophil-to-lymphocyte ratio (NLR), a widely assessed biomarker in most
common diseases, is typically evaluated before treatment initiation. However, data on NLR …

OBJECTIVE To determine whether neoadjuvant gemcitabine and cisplatin (GC) vs dose-
dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) before radical …

Objective The aim of this review is to summarize the current evidence and future
perspectives of bladder-sparing treatment for MIBC. Methods A non-systematic literature …

Objetivo Esta revisión tiene como objetivo resumir la evidencia actual y las perspectivas
futuras del tratamiento conservador de la vejiga para MIBC. Métodos En octubre de 2023 se …

Aim: To assess the significance of neoadjuvant chemotherapy has on survival in muscle
invasive bladder cancer compared to the absence of neoadjuvant chemotherapy …

Aim: To assess the significance of neoadjuvant chemotherapy has on survival in muscle
invasive bladder cancer compared to the absence of neoadjuvant chemotherapy …